Company Overview - Disc Medicine has been publicly listed for approximately three years and has experienced a productive journey during this period [3] - The company is on the verge of approval for its lead program and has a robust pipeline of additional programs progressing well [3] Clinical Programs - The presentation will cover three investigational agents: bitopertin, DISC-0974, and DISC-3405, which are not yet approved as therapies anywhere in the world [4] - The company aims to provide updates on the progress towards approval for its lead program and discuss launch strategies [5]

Biotech and healthcare names were among the notable movers in Wednesday's after-hours trading session, with several small-cap companies posting strong gains on the back of corporate updates and investor momentum.Plus Therapeutics, Inc. (PSTV) surged 8.40% to close at $0.31 after announcing the pricing of its underwritten public offering. The company is issuing 39,473,684 units, each consisting of one share of common stock and one warrant, at $0.38 per unit. Gross proceeds are expected to total approximatel ...

Company Overview - Liquidia is a biopharmaceutical company focused on improving inhaled drug delivery through proprietary formulations, particularly in the prostacyclin class of therapeutics [4]. Performance Highlights - The company had a spectacular year in 2025, indicating strong performance and growth [2]. Leadership Team - The presentation included key members of the leadership team, such as the CEO Roger Jeffs, CFO Michael Kaseta, and other executives, highlighting the collaborative effort in driving the company's vision [3].

Core Insights - Ascentage Pharma Group International presented its achievements in 2025 and outlined its global innovation strategy for 2026 at the J.P. Morgan Healthcare Conference [1][2] Company Overview - Ascentage Pharma is a global, commercial stage biopharmaceutical company focused on developing novel therapies for unmet medical needs in cancer [9] - The company has a diverse pipeline that includes inhibitors targeting key proteins in the apoptotic pathway and next-generation kinase inhibitors [9] Milestone Achievements - In 2025, Ascentage Pharma accelerated its global expansion, advancing product commercialization, clinical development, and pipeline innovation [2] - The company has established a strong foundation for sustained growth through its innovative engine in hematologic malignancies and solid tumors [2] Product Development - The two core products, Olverembatinib (a third-generation BCR-ABL inhibitor) and Lisaftoclax (a Bcl-2 inhibitor), are key growth drivers for 2026 [3] - Both products have shown significant progress in 2025 and are expected to generate a "dual-engine" effect for future growth [3] Clinical Studies and Innovations - Ascentage Pharma has made advancements in multiple clinical studies for its key drug candidates, presenting data at international academic congresses [4] - The company received IND clearance from the U.S. FDA for APG-3288, a novel BTK degrader, marking a significant step in targeted degradation [4][5] Pipeline Progress - The company is advancing several key clinical programs, including APG-5918 (EED inhibitor) and APG-2449 (FAK/ALK/ROS1 inhibitor), which are in various stages of clinical trials [6][7] - Multiple global registrational Phase III trials are progressing rapidly for its key products [5] Future Outlook - Potential milestones for 2026 include ongoing investigations of Olverembatinib, Lisaftoclax, and other pipeline candidates, which have not yet received FDA approval [8] - The company aims to continue its growth in commercial sales and expand patient accessibility across hospitals in China [12]

©2026 LIQUIDIA CORPORATION ALL RIGHTS RESERVED 2 Corporate Overview J.P. Morgan Healthcare Conference 2026 January 14, 2026 ©2026 LIQUIDIA CORPORATION ALL RIGHTS RESERVED Forward-looking statements This presentation includes, and our response to questions may include, forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 ("PSLRA"). All statements contained in this presentation other than statements of historical facts, including statements regarding our future ...

Core Insights - Samsung Epis Holdings is entering a significant phase in 2026, announcing six new candidates in its biosimilar pipeline, aiming for a total of 20 biosimilars by 2030 [1][4] - The company has received IND clearance for its first novel therapeutic candidate, SBE303, and plans to advance its clinical program this year [1][4] - Samsung Bioepis is expanding its portfolio beyond biosimilars, focusing on antibody-drug conjugates (ADCs) to address unmet medical needs [1][4] Biosimilar Pipeline - Samsung Bioepis currently has 11 biosimilars approved and launched in over 40 countries, covering 10 unique biological molecules [4] - The new biosimilar candidates include dupilumab, guselkumab, ixekizumab, fam-trastuzumab deruxtecan-nxki, vedolizumab, and ocrelizumab [4][6] - The company has launched several biosimilars, including adalimumab (Humira), etanercept (Enbrel), infliximab (Remicade), trastuzumab (Herceptin), and bevacizumab (Avastin) [3][5] Novel Therapeutics Development - SBE303 is Samsung Bioepis' first novel ADC targeting Nectin-4, with a Phase 1 clinical trial set to begin this year [4] - The company aims to introduce one novel therapeutic candidate into clinical studies each year [4] - Epis NexLab, a new subsidiary, is focused on developing a peptide-based drug delivery platform [4][9] Company Overview - Samsung Epis Holdings is dedicated to biopharmaceuticals and biotechnology, aiming to maximize corporate and shareholder value through R&D and strategic investments [7] - Samsung Bioepis, established in 2012, focuses on making healthcare accessible through innovative product development across various therapeutic areas [8] - Epis NexLab, established in 2025, is committed to driving innovation in next-generation biotechnology platforms [9]

NEW YORK, Jan. 14, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), today announced the effective date of its 1-for-6.25 share consolidation (reverse stock split) of the Company's issued and outstanding common shares. At a Special Meeting of Stockholders held on April 16, 2025, shareholders approved a special resolution authorizing the Board of Directors, at any time prior to the next annual meeting of shareholders, to implement a share consolidation at a r ...

Company Overview - Mereo is a rare disease company focused on developing treatments for conditions such as osteogenesis imperfecta (OI) [1][2] - The company has three clinical programs, with two of them being in late-stage development [2] Patient Impact - The presentation highlighted the personal stories of patients like Martin, who has Type 3 OI and has been on bisphosphonate treatment since he was six months old, experiencing hundreds of fractures [2] - The impact of OI on patients' lives is significant, but individuals like Martin are managing to pursue their education and careers despite the challenges [2]

J.P. Morgan 44th Annual Healthcare Conference Corporate Overview January 2026 Disclaimer and FLS This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, express or implied statements regarding Disc's expectations with respect to its preclinical studies, clinical trials and research and development programs, in particular with respect to bitopertin, DISC-0974 and DISC-3405, and any developments or resul ...

Zealand Pharma (OTCPK:ZLDP.Y) FY Conference January 14, 2026 04:30 PM ET Company ParticipantsAdam Steensberg - CEOConference Call ParticipantsNone - AnalystNoneGood afternoon and welcome to the Zealand session of the 44th J.P. Morgan Healthcare Conference. My name is Safiya Graff. I'm an analyst here at J.P. Morgan on the European Pharma and Biotech team. And today it's my pleasure to welcome Adam Steensberg, CEO of Zealand Pharma, to the conference. As a reminder, after the presentation, there will be a Q& ...